Rating Change
UBS reiterated its Buy rating on Merck & Co., Inc. (NYSE:MRK) on August 20, 2026.
UBS reiterated its Buy rating on Merck & Co., Inc. (NYSE:MRK) on August 20, 2026.

At publication ·
Merck & Co., Inc. (NYSE:MRK) · reiterate
At a glance
UBS reiterated its Buy rating on Merck & Co., Inc. (NYSE:MRK) on August 20, 2026.
Merck & Co., Inc. operates in the Healthcare sector. The stock currently trades at $149.25 with a market capitalization of $248.8B. The stock has gained 45.2% over the past 52 weeks.
Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Merck & Co., Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 20, 2026 | UBS | Buy | N/A |
| Aug 20, 2026 | BMO Capital | Outperform | N/A |
| Aug 20, 2026 | RBC Capital | Sector Perform | N/A |
| Aug 20, 2026 | Morgan Stanley | Overweight | N/A |
| Aug 12, 2026 | Daiwa Capital | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View MRK Stock Page
A rating of Buy from UBS reflects the analyst's outlook on Merck & Co., Inc. (NYSE:MRK). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MRK forecast page.
Current market data
NYSE · MRK
$148.99
Up: +$3.56 · +2.39%
Live quote updated
Keep reading